Investing.com – Citizens lowered its price target on Avalo Therapeutics Inc. () to $55 from $62 while maintaining a Market Outperform rating. The new target sits below the analyst consensus high of $62 but above the low of $35, reflecting cautious optimism despite the stock’s recent 13% decline over the past week.
The firm cited a recent equity financing as the reason for the reduced price target. Avalo raised net proceeds of approximately $40 million from an equity offering that followed the announcement of Phase 2 results.
The company reported first-quarter 2026 financial results and business updates, outlining plans to advance abdakibart into registrational Phase 3 studies. Avalo ended the first quarter with $82 million in cash. According to InvestingPro analysis, the company holds more cash than debt on its balance sheet, though the stock currently trades slightly above its Fair Value. Investors can access comprehensive financial health metrics and over 15 additional ProTips on the platform.
The Phase 2 LOTUS trial demonstrated positive results, according to Citizens. The firm described the magnitude of benefit as robust and competitive.
Citizens maintained its Market Outperform rating on the stock. The firm’s price target is derived from a risk-adjusted discounted cash flow model.
In other recent news, Avalo Therapeutics has announced significant developments that are capturing the attention of investors. The company reported positive results from its Phase 2 LOTUS trial of abdakibart, which successfully met its primary endpoint in treating moderate to severe hidradenitis suppurativa. This trial demonstrated response rates of 42.2% for the 150 mg dose and 42.9% for the 300 mg dose at Week 16, marking the highest rates observed in a trial of this size or larger. Following these results, Citizens raised its price target for Avalo Therapeutics from $52 to $62, maintaining a Market Outperform rating due to the drug’s blockbuster potential.
Additionally, Avalo Therapeutics has priced a $375 million stock offering, involving 19,730,000 shares of common stock and pre-funded warrants to purchase 1,400,000 shares. The common stock is priced at $17.75 per share, while the pre-funded warrants are priced at $17.749 per warrant. The company has also granted underwriters a 30-day option to purchase up to 3,169,500 additional shares under the same terms. These recent developments highlight Avalo Therapeutics’ strategic moves to capitalize on positive trial data and secure additional funding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.